Does alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome? A population-based study in Kerala, India

Annals of the American Thoracic Society

Volumn 11, Issue 5, 2014, Pages 712-715

  Duraisamy, Karthickeyan ^a   Mrithyunjayan, Sunilkumar ^b   Ghosh, Smita ^c   Nair, Sreenivas Achuthan ^a   Balakrishnan, Shibu ^a   Subramoniapillai, Jayasankar ^b   Oeltmann, John E ^c   Moonan, Patrick K ^c   Kumar, Ajay M V ^d  

^a WHO Country Office for India   (India)

^b Directorate of Health Services   (India)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

Alcohol; India; Multidrug resistant tuberculosis; Multidrug resistant tuberculosis treatment outcome; Tuberculosis

Indexed keywords

ALCOHOL; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ALCOHOL CONSUMPTION; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DRINKING BEHAVIOR; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEALTH PROGRAM; HUMAN; INDIA; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NEUROPATHY; OBESITY; OTOTOXICITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; RETROSPECTIVE STUDY; SMOKING; SUICIDAL IDEATION; TUBERCULOSIS CONTROL; CLINICAL TRIAL; HEALTH SURVEY; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; RISK ASSESSMENT; RISK FACTOR; SPUTUM; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; ALCOHOL DRINKING; ANTITUBERCULAR AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INDIA; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPUTUM; SURVIVAL RATE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84903629574     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201312-447OC     Document Type: Article

References (36)

1. World Health Organization. Global tuberculosis report 2013. Geneva, Switzerland: WHO/HTM/TB/2013.11.
2. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 Update. Geneva, Switzerland: WHO; 2011.
3. Revised National Tuberculosis Control Programme. Guidelines on programmatic management of drug resistant TB (PMDT) in India-May 2012, Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, New Delhi [accessed 2012 Jun 14]. Available from: http://www.tbcindia. nic.in/documents.html
4. Marks SM, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S, Salcedo K, Oh P, Graviss EA, Colson PW, et al.; TB Epidemiologic Studies Consortium. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. Emerg Infect Dis 2014;20:812-821.
5. Resch SC, Salomon JA, Murray M, Weinstein MC. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 2006;3:e241.
6. Andrews JR, Shah NS, Weissman D, Moll AP, Friedland G, Gandhi NR. Predictors of multidrug-and extensively drug-resistant tuberculosis in a high HIV prevalence community. PLoS ONE 2010;5:e15735.
7. Flor de Lima B, Tavares M. Risk factors for extensively drug-sistant tuberculosis: a review. Clin Respir J. 2014;8:11-23.
8. Shin SS, Keshavjee S, Gelmanova IY, Atwood S, Franke MF, Mishustin SP, Strelis AK, Andreev YG, Pasechnikov AD, Barnashov A, et al.Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 2010;182:426-432.
9. Kim DH, Kim HJ, Park S-K, Kong S-J, Kim YS, Kim T-H, Kim EK, Lee KM, Lee S-S, Park JS, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:113-119.
10. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012;54:579-581.
11. Falzon D, Jaramillo E, Wares F, Zignol M, Floyd K, Raviglione MC. Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis 2013;13:690-697.
12. Sachdeva KS, Kumar A, Dewan P, Kumar A, Satyanarayana S. New vision for Revised National Tuberculosis Control Programme (RNTCP): universal access-"reaching the un-reached". Indian J Med Res 2012;135:690-694.
13. Dsa K, Mrithyunjayan S, Ghosh S, Sreenivas A, Balakrishnan S, Subramoniapillai J, Moonan P, Kumar A. Treatment outcomes of persons with multidrug resistant tuberculosis, Kerala, India, 2009-2010 [abstract]. Int J Tuberc Lung Dis 2013;17:5483-5484.
14. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and metaanalysis. Lancet Infect Dis 2009;9:153-161.
15. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 2009;4:e6914.
16. Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb) 2012;92: 397-403.
17. Das SK, Balakrishnan V, Vasudevan DM. Alcohol: its health and social impact in India. Med Soc 2006;19:94A9.
18. Sugathan TN, Soman CR, Sankaranarayanan K. Behavioural risk factors for non communicable diseases among adults in Kerala, India. Indian J Med Res 2008;127:555-563.
19. Kerala State Beverages Corporation (KSBC). April 2013 [accessed 2014 May 22]. Available from: http://www.ksbc.kerala.gov.in/
20. Oeltmann JE, Kammerer JS, Pevzner ES, Moonan PK. Tuberculosis and substance abuse in the United States, 1997-2006. Arch Intern Med 2009;169:189-197.
21. Rehm J, Baliunas D, Borges GLG, Graham K, Irving H, Kehoe T, Parry CD, Patra J, Popova S, Poznyak V, et al. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction 2010;105:817-843.
22. Jakubowiak WM, Bogorodskaya EM, Borisov SE, Danilova ID, Kourbatova EV. Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions. Int J Tuberc Lung Dis 2007;11:46-53.
23. Parry C, Rehm J, Poznyak V, Room R. Alcohol and infectious diseases: an overlooked causal linkage? Addiction 2009;104:331-332.
24. Rehm J, Samokhvalov AV, Neuman MG, Room R, Parry C, Lönnroth K, Patra J, Poznyak V, Popova S. The association between alcohol use, alcohol use disorders and tuberculosis (TB): a systematic review. BMC Public Health 2009;9:450.
25. Driver CR, Matus SP, Bayuga S, Winters AI, Munsiff SS. Factors associated with tuberculosis treatment interruption in New York City. J Public Health Manag Pract 2005;11:361-368.
26. Podewils LJ, Gler MT, Quelapio MI, Chen MP. Patterns of treatment interruption among patients with multidrug-resistant TB (MDR TB) and association with interim and final treatment outcomes. PLoS ONE 2013;8:e70064.
27. Dannenberg AM Jr. Immune mechanisms in the pathogenesis of pulmonary tuberculosis. Rev Infect Dis 1989;11:S369-S378.
28. Bermudez LE, Wu M, Martinelli J, Young LS. Ethanol affects release of TNF and GM-CSF and membrane expression of TNF receptors by human macrophages. Lymphokine Cytokine Res 1991;10:413-419.
29. Rimland D. Mechanisms of ethanol-induced defects of alveolar macrophage function. Alcohol Clin Exp Res 1984;8:73-76.
30. Szabo G, Mandrekar P, Catalano D. Inhibition of superantigen-induced T cell proliferation and monocyte IL-1 beta, TNF-alpha, and IL-6 production by acute ethanol treatment. J Leukoc Biol 1995;58: 342-350.
31. Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, Qin L, Szabo G, Wheeler M, Zou J. Cytokines and alcohol. Alcohol Clin Exp Res 2006;30:720-730.
32. Greenfield SF, Shields A, Connery HS, Livchits V, Yanov SA, Lastimoso CS, Strelis AK, Mishustin SP, Fitzmaurice G, Mathew TA, et al. Integrated management of physician-delivered alcohol care for tuberculosis patients: design and implementation. Alcohol Clin Exp Res 2010;34:317-330.
33. Shin S, Livchits V, Connery HS, Shields A, Yanov S, Yanova G, Fitzmaurice GM, Nelson AK, Greenfield SF; Tomsk Tuberculosis Alcohol Working Group. Effectiveness of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia. Addiction 2013;108:1387-1396.
34. Thomas B, Suhadev M, Mani J, Ganapathy BG, Armugam A, Faizunnisha F, Chelliah M, and Wares F. Feasibility of an alcohol intervention programme for TB patients with alcohol use disorder (AUD)-a qualitative study from Chennai, South India. PLoS ONE 2011;6:e27752.
35. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, Laserson KF, Wells CD. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005;365:318-326.
36. World Health Organization. Management of MDR-TB: a field guide. A companion document to Guidelines for the Programmatic Management of Drug-resistant Tuberculosis (WHO/HTM/TB/ 2008.402a). Geneva, Switzerland: World Health Organization; 2009.